The authors assessed whether measures of hippocampal water diffusivity at baseline can predict future progression to Alzheimer disease (AD) in amnestic mild cognitive impairment (aMCI). Higher baseline hippocampal diffusivity was associated with a greater risk of progression to AD in aMCI (p ϭ 0.002). Magnetic resonance diffusion-weighted imaging may help identify patients with aMCI who will progress to AD as well as or better than structural MRI measures of hippocampal atrophy.
People with amnestic mild cognitive impairment (aMCI) are recognized as an important clinical group in identifying early markers for Alzheimer disease (AD). 1 Although most people with aMCI progress to AD, the rate of progression to AD varies among these individuals. This provides the incentive to develop neuroimaging markers that can predict the rate of progression to AD in aMCI. Diffusion-weighted MRI (DWI) is sensitive to the random motion of water molecules in brain tissue. Measures of apparent diffusion coefficient (ADC) from DWI can quantify the alterations in water diffusivity resulting from microscopic structural changes. In a previous crosssectional study, we found that hippocampal ADC values were higher in people with aMCI and AD than in cognitively normal elderly subjects. 2 Our objective in this study was to determine whether baseline hippocampal ADC can predict future progression to AD in people with aMCI and whether baseline hippocampal ADC may better predict progression to AD when combined with hippocampal volumetry in a multivariate model.
Methods.
Between September 1998 and June 2000, 24 patients with aMCI and 60 cognitively normal elderly subjects were consecutively recruited for a DWI study from the Alzheimer's Disease Research Center (ADRC)/Alzheimer's Disease Patient Registry (ADPR) at the Mayo Clinic, Rochester, MN. We previously published the cross-sectional data on 19 of the patients with aMCI and 55 of the normal subjects. 2 This study was approved by the Mayo Institutional Review Board, and informed consent for participation was obtained from every subject and/or an appropriate surrogate. Individuals participating in the ADRC/ADPR undergo approximately annual clinical evaluations, brain MRI, and routine laboratory tests. Subjects with structural abnormalities that could produce dementia, such as cortical infarction, tumor, subdural hematoma, or who had treatments or concurrent illnesses interfering with cognitive function other than AD were excluded. The diagnosis of probable AD was made according to the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised 3 criteria for dementia, and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association 4 criteria for AD. Patients with aMCI met the criteria of Petersen et al. 1 Subjects were independently functioning community dwellers with no neurologic or psychiatric conditions.
The MRI and DWI studies were performed on a 1.5-T magnetic resonance (MR) scanner (Signa; GE). Single-shot echo planar-fluid attenuated inversion recovery (EPI-FLAIR) DWI was performed in a coronal plane with TR/TE/TI ϭ 9999/93/2200 milliseconds. A FLAIR image volume with b ϭ 0 s/mm 2 and DWI with b ϭ 1,000 s/mm 2 in three orthogonal directions were acquired at identical slice positions. Average ADC maps were computed pixel by pixel with the Stejskal and Tanner equation. 5 Coronal T1-weighted spin echo images from the same slice locations as DWI were obtained to be used as anatomic reference for defining the hippocampal regions of interest (ROIs) for ADC measurements. Hippocampal ADC were determined from ROIs traced on the most posterior coronal slice that included the hippocampal heads on EPI-FLAIR images. These traces then concurrently appear on the ADC maps (figure 1). The borders of the hippocampal heads in all subjects were traced by the same investigator (K.K.), who was blinded to the clinical diagnosis. Special attention was paid to excluding CSF from the ROIs.
Hippocampal volume measurements were traced on T1weighted, three-dimensional, volumetric spoiled-gradient recalled echo sequence images. 6 Hippocampal volumes of each subject were normalized for intersubject variation in head size. Volumes were then converted to normal deviates, referred to as W scores, using age-and gender-specific normal percentiles based on a previous study. 7 A value of 0 ϭ 50th percentile, ϩ1.64 ϭ 95th percentile, Ϫ1.64 ϭ 5th percentile among subjects.
We used a series of univariate Cox proportional hazards models to separately estimate the effect of baseline hippocampal ADC, hippocampal W scores, age, gender, education, and Mini-Mental State Examination (MMSE) scores on the relative hazard of conversion from aMCI to AD. The two predictors that were significant univariately were then combined in a bivariate Cox proportional hazards model. tion, or gender distribution between subjects and patients with aMCI (p Ͼ 0.05) (table) . At baseline, hippocampal ADCs of subjects with aMCI were higher (p ϭ 0.02), and hippocampal W scores were lower (p Ͻ 0.001) than those of subjects. The more atrophic hippocampi were associated with higher hippocampal ADC values (Pearson correlation estimate ϭ Ϫ0.47, p ϭ 0.03) (see figure E-1 on the Neurology Web site at www.neurology.org). The Kaplan-Meier estimates of the probability of conversion to AD in aMCIs with hippocampal ADC values above versus at or below 888 ϫ 10 Ϫ6 mm 2 /s (median hippocampal ADC among aMCI stables) are demonstrated in figure 2 .
The Cox proportional hazards model showed that both higher hippocampal ADC values (p ϭ 0.002) and lower (more atrophic) hippocampal W scores (p ϭ 0.02) in subjects with aMCI at baseline are associated with a higher relative risk of progression to AD (see figure E-2). Based on this model, we estimate that among subjects with aMCI, a 65.8 ϫ 10 Ϫ6 mm 2 /s increase in hippocampal ADC (1 SD among aMCI stables), increases the relative risk of conversion to AD by a factor of 3.1 (95% CI ϭ 1.5 to 6.4). A 1.24-point decrease in hippocampal W scores (1 SD among aMCI stables) increases the relative risk of conversion to AD by a factor of 2.5 (95% CI ϭ 1.0 to 6.2). Age, gender, education, and MMSE scores were not related to time to conversion among patients with aMCI (p Ͼ 0.05). The likelihood ratio test on the Cox proportional hazards model, which included both hippocampal ADC and W scores, showed that hippocampal ADC and W scores describe the data better than a model with only the W score (p ϭ 0.02). Conversely, adding the hippocampal W score to a model with hippocampal ADC did not fit the data better than hippocampal ADC alone (p ϭ 0.20).
Discussion.
Most people with aMCI have early AD pathology in the mediotemporal limbic cortex. 8 Elevated hippocampal ADC in people with aMCI who soon progress to AD indicates that DWI is sensitive to subtle variations in disease stage in the hippocam- Ϫ1.32 Ϯ 1.14 * Right and left hippocampal ADC were not different among normals nor among those with aMCI. Therefore, they were averaged for all analyses. † MMSE of normals at baseline were higher than aMCI (rank-sum test, p ϭ 0.02), and hippocampal ADC of patients with aMCI at baseline were higher than those of normals (t test, p ϭ 0.02). Hippocampal volumes (W scores) of patients with aMCI at baseline were lower than those of normals (t test, p Ͻ 0.001). ‡ The large difference in follow-up time between aMCI stables and converters is due to censoring at the time of conversion. aMCI ϭ amnestic mild cognitive impairment; MMSE ϭ Mini-Mental State Examination. pus before the clinical diagnosis of AD is possible. Increased diffusivity in the brains of people with AD has been attributed to the loss of neuron cell bodies, axons, and dendrites, causing expansion of the extracellular space where water diffusivity is faster. 2, 9, 10 Loss of hippocampal neuron cell bodies, synapses, and dendrites early in the pathologic progression of AD lead to macroscopic structural changes in the hippocampus that can be measured by hippocampal volumetry. The negative correlation that we found between hippocampal diffusivity and volume in people with aMCI further indicates that both MR techniques are sensitive to the same neurodegenerative process in early AD.
Although hippocampal ADC improved the ability of hippocampal volume measurements to predict progression to AD in aMCI, hippocampal volume measurements did not have any additional effect on hippocampal ADC in predicting progression to AD. This finding suggests that elevated hippocampal diffusivity predicts progression to AD in aMCI as well as or better than hippocampal atrophy. DWI is sensitive to alterations in water diffusivity in the hippocampus at the microscopic level, which may be apparent earlier than the macroscopic change measured with hippocampal volumetry in patients with aMCI who progress to AD. With both techniques, overlap between values in aMCI stables and converters limits the diagnostic predictive value in individual subjects. However, like MR volumetry, DWI may be useful for monitoring drug effects during the progression of aMCI to AD for early therapeutic interventions. The plots represent patients with aMCI with a hippocampal apparent diffusion coefficient (ADC) of Յ888 ϫ 10 Ϫ6 mm 2 /s (median hippocampal ADC among patients with aMCI) and patients with aMCI with a hippocampal ADC of Ͼ888 ϫ 10 Ϫ6 mm 2 /s.
